National Policy on Traditional Medicine and Regulation of Herbal Medicines - Report of a WHO Global Survey
(2005; 168 pages) View the PDF document
Table of Contents
View the documentAcknowledgements
View the documentExecutive summary
View the documentAcronyms, abbreviations and definitions
View the documentWHO Regions
Open this folder and view contents1. Introduction
Open this folder and view contents2. National policy on traditional medicine and complementary/alternative medicine
Close this folder3. The regulatory situation of herbal medicines
View the document3.1 Law or regulation on herbal medicines
View the document3.2 Regulatory status of herbal medicines
View the document3.3 Claims
View the document3.4 Pharmacopoeias
View the document3.5 Monographs on herbal medicines
View the document3.6 Manufacture of herbal medicines
View the document3.7 Safety and herbal medicines
View the document3.8 Registration system for herbal medicines
View the document3.9 Herbal medicines and the essential drug list
View the document3.10 Post marketing surveillance of herbal medicines
View the document3.11 The sale of herbal medicines
View the document3.12 Annual market sales of herbal medicines
Open this folder and view contents4. Member States, WHO and herbal medicines
Open this folder and view contents5. Country summaries
View the documentReferences
View the documentAnnex 1. Text of survey instrument
 

3.10 Post marketing surveillance of herbal medicines

Countries were first asked whether they had a post marketing surveillance system for herbal medicines. If countries responded “yes”, the next question asked whether there is a national system to monitor adverse effects of herbal medicines. If such a system exists, the date of establishment was requested. If the Member State reported that a post marketing surveillance system for herbal medicines did not exist, the next question asked if there are plans to establish such a system.

A total of 114 countries answered the first question regarding the existence of a post-marketing surveillance system for herbal medicines. Fifty-nine countries, or 42%, reported that they had such a system (Figure 38), with many indicating in a comment that the surveillance system is the same as for conventional pharmaceuticals.


Figure 38. Post-marketing surveillance system for herbal medicines

Of those countries that reported the existence of a post marketing surveillance system, 53, or 90%, reported that they also had a national system to monitor adverse effects of herbal medicines (Figure 39). Of these 53 countries, 37 provided information on the year of establishment of national systems to monitor adverse effects of herbal medicines. The majority have been founded in the last 15 years (Figure 40).


Figure 39. National system to monitor adverse effects relating to herbal medicines


Figure 40. Number of Member States with a national system to monitor adverse effects relating to herbal medicines, by year

to previous section to next section
 

Last updated: May 3, 2013